Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100

Grivas, P.Park, S. H.Voog, E.Caserta, C.Perez Valderrama, B.Gurney, H.Kalofonos, H.Radulovic, S.Demey, W.Ullen, A.Loriot, Y.Sridhar, S. S.Tsuchiya, N.Kopyltsov, E.Gupta, S.Huang, B.Costa, N.Blake-Haskins, J. A.di Pietro, A.Powles, T. B.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27220enAvelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100conference outputopen access10.1016/j.annonc.2020.08.7761569-8041http://www.annalsofoncology.org/article/S0923753420407720/pdf573469100700